Trial · NCT00550459
Outcomes29
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores) | baseline and Day 22 | Analysis based upon observed cases (OC). | Z-score | MEAN |
| SECONDARY | Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests | baseline and Day 22 | ITT population with OC | Z-score | MEAN |
| SECONDARY | Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test | baseline and Day 22 | ITT population with OC | Z-score | MEAN |
| SECONDARY | Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test | baseline and Day 22 | ITT population with OC | Z-score | MEAN |
| SECONDARY | Change From Baseline in Overall Neurocognitive Composite Score | baseline and Day 22 | ITT population with OC | Z-score | MEAN |
| SECONDARY | Change From Baseline in Gait Test (Timed Get-Up-and-Go Test) | baseline and Day 22 | ITT population with OC | Seconds | MEAN |
| SECONDARY | Change From Baseline in Postural Stability Test | baseline and Day 22 | ITT population with LOCF (this group includes missing values) | Z-score | MEAN |
| SECONDARY | Change From Baseline in Serum Sodium; ITT Population | Baseline and Day 22 | ITT population with OC | mEq/L | MEAN |
| SECONDARY | Number of Patients With Vital Sign Abnormalities: Blood Pressure | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Vital Sign Abnormalities: Pulse Rate | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Vital Sign Abnormalities: Body Weight | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Vital Sign Abnormalities: Body Temperature | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT) | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Hematology Laboratory Abnormalities: Neutrophils | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN) | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
| SECONDARY | Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose | 28 days | Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00550459/outcomes